{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:31:29Z","timestamp":1791599489898,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for obesity and type 2 diabetes, yet substantial variability in weight-loss response remains poorly understood. We conducted a retrospective cohort study using de-identified electronic health records and performed 1:1 propensity matching on age, sex, type 2 diabetes status, baseline BMI and weight, index year, and follow-up duration. The matched cohorts included 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients. Patients were categorized by maximum weight loss over 2 years into five response groups. Adverse events were identified through AI-enabled curation of clinical notes. Weight-loss trajectories, demographic patterns, adverse-event profiles, and pre- to posttreatment disease-prevalence changes were compared across drugs. Patients treated with tirzepatide lost more weight than those treated with semaglutide (mean reduction, 14.7 vs. 10.8%; P &amp;lt; 0.001). High-response rates (\u226515% weight loss in year 1) were nearly doubled with tirzepatide (42.6 vs. 21.6%; P &amp;lt; 0.001), accompanied by faster monthly weight-loss velocity (2.54 vs. 2.18%). AI-enabled curation showed that tirzepatide was associated with lower prevalence of gastrointestinal and systemic adverse events. For both tirzepatide and semaglutide, women were more represented among high responders than the minimal weight-loss group (&amp;lt;5% weight loss) and White patients were more represented among high responders, whereas Black and Hispanic patients were more represented among the minimal weight-loss group. In this large, propensity-matched real-world cohort, tirzepatide was associated with greater and faster weight loss than semaglutide, with marked demographic variations in outcomes, highlighting the need for next-generation obesity clinical trials and routine care decisions to incorporate the growing body of evidence from widespread use of incretin therapies across diverse patient populations.<\/jats:p>","DOI":"10.1093\/pnasnexus\/pgag171","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:54Z","timestamp":1781614914000},"source":"Crossref","is-referenced-by-count":4,"title":["Weight-loss dynamics with tirzepatide versus semaglutide"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-3214","authenticated-orcid":false,"given":"A J","family":"Venkatakrishnan","sequence":"first","affiliation":[{"name":"Metabolism Agentic Intelligence Atlas (MAIA), nference , 1 Main Street, East Arcade Building, Cambridge, MA 02142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Murugadoss","sequence":"additional","affiliation":[{"name":"Metabolism Agentic Intelligence Atlas (MAIA), nference , 1 Main Street, East Arcade Building, Cambridge, MA 02142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-9211","authenticated-orcid":false,"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[{"name":"Metabolism Agentic Intelligence Atlas (MAIA), nference , 1 Main Street, East Arcade Building, Cambridge, MA 02142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026061609014607400_pgag171-B1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026061609014607400_pgag171-B2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.2337\/dc23-1135","article-title":"Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1\u20134","volume":"46","author":"Ma\u0142ecki","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061609014607400_pgag171-B3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061609014607400_pgag171-B4","doi-asserted-by":"crossref","first-page":"e017177","DOI":"10.1136\/bmjgh-2024-017177","article-title":"Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps","volume":"9","author":"Jeyakumar","year":"2024","journal-title":"BMJ Glob Health"},{"key":"2026061609014607400_pgag171-B5","doi-asserted-by":"crossref","first-page":"e58227","DOI":"10.7554\/eLife.58227","article-title":"Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis","volume":"9","author":"Wagner","year":"2020","journal-title":"Elife"},{"key":"2026061609014607400_pgag171-B6","doi-asserted-by":"crossref","first-page":"e29812","DOI":"10.2196\/29812","article-title":"Analyzing patient trajectories with artificial intelligence","volume":"23","author":"Allam","year":"2021","journal-title":"J Med Internet Res"},{"key":"2026061609014607400_pgag171-B7","author":"Akagi","year":"2025"},{"key":"2026061609014607400_pgag171-B8","doi-asserted-by":"publisher","first-page":"e13573","DOI":"10.1200\/JCO.2023.41.16_suppl.e13573","article-title":"Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma","volume":"41","author":"Pawlowski","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061609014607400_pgag171-B9","doi-asserted-by":"crossref","first-page":"e64697","DOI":"10.2196\/64697","article-title":"A deep learning-enabled workflow to estimate real-world progression-free survival in patients with metastatic breast cancer: study using deidentified electronic health records","volume":"11","author":"Varma","year":"2025","journal-title":"JMIR Cancer"},{"key":"2026061609014607400_pgag171-B10","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.patter.2021.100255","article-title":"Building a best-in-class automated de-identification tool for electronic health records through ensemble learning","volume":"2","author":"Murugadoss","year":"2021","journal-title":"Patterns (N Y)"},{"key":"2026061609014607400_pgag171-B11","doi-asserted-by":"publisher","author":"Murugadoss","year":"20  2024","DOI":"10.1101\/2024.06.20.24308896"},{"key":"2026061609014607400_pgag171-B12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"key":"2026061609014607400_pgag171-B13","doi-asserted-by":"publisher","author":"Devlin J, Chang M-W, Lee K, Toutanova K.","year":"2019","DOI":"10.18653\/v1\/N19-1423"},{"key":"2026061609014607400_pgag171-B14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061609014607400_pgag171-B15","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1111\/dom.70004","article-title":"Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026061609014607400_pgag171-B16","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"2026061609014607400_pgag171-B17","doi-asserted-by":"crossref","first-page":"e089477","DOI":"10.1136\/bmjopen-2024-089477","article-title":"Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis","volume":"15","author":"Squire","year":"2025","journal-title":"BMJ Open"},{"key":"2026061609014607400_pgag171-B18","doi-asserted-by":"crossref","first-page":"e2455222","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors associated with semaglutide initiation among adults with obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026061609014607400_pgag171-B19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["PNAS Nexus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/5\/6\/pgag171\/68527403\/pgag171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/5\/6\/pgag171\/68527403\/pgag171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:55Z","timestamp":1781614915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article\/doi\/10.1093\/pnasnexus\/pgag171\/8708114"}},"subtitle":[],"editor":[{"given":"Nancy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/pnasnexus\/pgag171","relation":{},"ISSN":["2752-6542"],"issn-type":[{"value":"2752-6542","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,30]]},"article-number":"pgag171"}}